Market Overview

Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is 'Born to Run'


Canadian biotech Zymeworks Inc. (NYSE: ZYME) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug, leading to a more bullish stance on the company’s stock from Raymond James.

The Analyst

Raymond James analyst David Novak upgraded Zymeworks from Outperform to Strong Buy while upping the target price from $36 to $40.

The Thesis

The new data presented at the ESMO conference demonstrates Zymeworks "was born to run," Novak wrote in a note.

The Vancouver-based biotech’s latest results, demonstrating what Novak called “highly encouraging antitumor activity,” could be a major step forward, he said, with the potential to “in time, transform the HER2 therapeutic landscape.

“With multiple potential clinical catalysts anticipated in the coming months, we expect additional positive data readouts, and thus are upgrading ZYME to a Strong Buy,” Novak wrote.

Price Action

Zymeworks shares traded around $24.79 at publication time.

Related Links:

The Week Ahead In Biotech: Conference Presentations, IPOs Hit Top Gear

The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study

Latest Ratings for ZYME

Mar 2020H.C. WainwrightReiteratesBuy
Feb 2020Stifel NicolausMaintainsBuy
Jan 2020Wells FargoMaintainsOverweight

View More Analyst Ratings for ZYME
View the Latest Analyst Ratings


Related Articles (ZYME)

View Comments and Join the Discussion!

Posted-In: David Novak ESMOAnalyst Color Biotech Upgrades Price Target Analyst Ratings General

Latest Ratings

RCUSSVB LeerinkReiterates42.0
ULTAWells FargoMaintains300.0
CRMWells FargoMaintains215.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at